Opportunity for JNC VII

Journal of Clinical Hypertension

Volumn 5, Issue 1, 2003, Pages 15-16

  Handler, Joel ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG INDUSTRY; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICAL SOCIETY; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PROTEINURIA; UNITED STATES;

EID: 0037274754     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.02190.x     Document Type: Note

References (10)

1. Kurtzman NA. Conflicts of interest and ethical issues in the design and reporting of clincial issues. Seventeenth Annual Scientific Meeting of the American Society of Hypertension. New York, NY; May 17, 2001.
2. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345: 861-869.
3. Lewis EJ, Hunsicker LG, Clarde WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
4. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
5. Lindholm LH, Ibsen H, Dahor B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:1004-1010.
6. Sica DA. Premature termination of clinical trials-lessons learned. J Clin Hypertens. 2002;4:219-225.
7. Hrachovec JB. Reporting of 6-month vs. 12-month data in a clinical trial of celecoxib [letter]. JAMA. 2001;286:2398.
8. Moser M. Comments on medical research and the publication of scientific papers. J Clin Hypertens. 2001;3:277-278.
9. Schulman KA, Seils DM, Timbie JW, et al. A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med. 2002; 347:1335-1341.
10. Davidoff FD, De Angelis CD, Drazen JM, et al. Sponsorship, authorship, and accountability [editorial]. N Engl J Med. 2001;345:825-826.